Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus ICE chemotherapy for unresectable advanced hepatoblastoma
ChiCTR2500103476Phase 2Not yet recruiting
- Sponsor
- Renji Hospital
- Start
- May 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sintilimab, ifosfamide, carboplatin and etoposide in hepatoblastoma (2 arms), sponsored by Renji Hospital. Primary endpoints: Objective Response Rate and Incidence and grading of adverse events and serious adverse events. Planned start May 2025; status: not yet recruiting.
02
Drugs
sintilimabifosfamidecarboplatinetoposide
03
Conditions
hepatoblastoma
Beyond the preview
Go deeper on ChiCTR2500103476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103476.